Delivery Order SPE2DB20D3101-SPE2DB25FRUL7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $9,864.24 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with a completion deadline of August 20, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol, and this delivery order represents a routine...
- The Defense Logistics Agency awarded a delivery order valued at $6,515.15 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens, with a completion date of September 2, 2025. This competitive award, issued on August 29, 2025, utilizes firm fixed pricing and carries no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and...
- The Defense Logistics Agency awarded a delivery order valued at $2,603.55 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 4, 2025. This non-competitive delivery order represents a firm fixed-price transaction executed on August 1, 2025, with the product to be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol levels and...
- The Defense Logistics Agency awarded a delivery order valued at $13,727.57 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injector pens. This non-competitive, firm fixed-price delivery order was awarded on September 9, 2025, with a completion date of September 10, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Repatha (evolocumab) is a PCSK9 inhibitor used to lower cholesterol and reduce cardiovascular risk in eligible...
- The Defense Logistics Agency awarded a delivery order valued at $1,562.13 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Repatha is a PCSK9 inhibitor indicated for cholesterol management in high-risk cardiovascular patients, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $1,802.00 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the awardee's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol levels in patients with...
- The Defense Logistics Agency awarded a delivery order valued at $1,962.21 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol levels, and this delivery...
- The Defense Logistics Agency awarded a delivery order valued at $43,228.79 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside contract was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Repatha is a prescription medication used to lower cholesterol and reduce cardiovascular risk, representing a...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with a completion date of July 23, 2025. This non-competitive, firm fixed-price delivery order was issued on July 22, 2025, and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Repatha is a prescription medication used to treat high cholesterol and reduce the risk of cardiovascular disease. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,203.06 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price contract, issued on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation, and performance will occur at...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRUL7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $42,622.35 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and represents a standalone procurement from the vendor's location in Conshohocken, Pennsylvania. Repatha is a prescription medication used for cholesterol management and cardiovascular disease prevention, indicating this delivery supports federal healthcare needs across the Department of Defense medical supply chain. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime IDC serves as a comprehensive pharmaceutical support vehicle enabling AmerisourceBergen to supply medications, vaccines, and medical supplies to military healthcare programs globally. The company's extensive pharmaceutical distribution capabilities and consistent performance on federal contracts have established it as a critical vendor for DLA's medical procurement operations, supporting the Defense Health Agency and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $42.6k | 9/4/25 |